Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Matosinhos – page 51

691 clinical trials in Matosinhos, Portugal across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Matosinhos at a glance
691
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

691 trials in Matosinhos

Open in trial search

Neoplasm

Not recruiting

Study on the Effectiveness of Inavolisib, Atezolizumab, and Entrectinib in Patients with Advanced or Metastatic Solid Tumors

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Bladder cancer

Not recruiting

Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Study on Golcadomide and R-CHOP Drug Combination for Patients with Untreated High-risk Large B-cell Lymphoma

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Celgene Corp.

Lupus nephritis

Not recruiting

Study on the Effectiveness and Safety of Iptacopan with Drug Combination for Adults with Active Lupus Nephritis Class III-IV, +/- V

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Short stature+3

Not recruiting

Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Somapacitan
  • Sponsor:Novo Nordisk A/S

Study on Trastuzumab and Pertuzumab for Patients with HER2-Positive Breast Cancer Using a Response-Adapted Strategy

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Medica Scientia Innovation Research S.L.

Dermatitis atopic

Not recruiting

Study on Dose Flexibility of Upadacitinib for Adults with Moderate to Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Study of MK-7684A with Chemoradiotherapy Compared to Chemoradiotherapy with Durvalumab for Patients with Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Lupus nephritis

Not recruiting

Study on Zetomipzomib for Patients with Active Lupus Nephritis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Methylprednisolone
  • Sponsor:Kezar Life Sciences Inc.

Malignant melanoma

Not recruiting

Study of mRNA-4157 and Pembrolizumab for Patients with High-Risk Stage II-IV Melanoma

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Dermatitis atopic

Not recruiting

Study of Upadacitinib and Topical Corticosteroids for Adolescents and Adults with Moderate to Severe Eczema

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Hydrocortisone
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Matosinhos

What the registry says about research in the country

01 Neurological Disorders

Innovative research focusing on Frontotemporal Dementia and various forms of Multiple Sclerosis, including primary progressive and secondary progressive variants. Studies are evaluating novel therapeutic approaches and long-term treatment options.

  • Frontotemporal Dementia Treatment
  • Multiple Sclerosis Management
  • Epilepsy Interventions

Clinical investigations include assessment of new compounds for refractory focal onset epilepsy and progressive neurological conditions.

02 Respiratory Medicine

Comprehensive studies addressing Pulmonary Fibrosis and chronic respiratory conditions. Research focuses on innovative treatments for chronic rhinosinusitis and progressive lung diseases.

  • Idiopathic Pulmonary Fibrosis
  • Chronic Rhinosinusitis
  • COPD Management

Trials aim to improve lung function and reduce disease progression in various respiratory conditions.

03 Cardiovascular Studies

Advanced research in Heart Failure and stroke prevention, particularly focusing on patients with atrial fibrillation. Studies evaluate new treatment combinations and preventive strategies.

  • Stroke Prevention
  • Heart Failure Management
  • Systemic Embolism Prevention

Research includes comparative studies of new medications for cardiac conditions and prevention strategies.

04 Oncology Research

Targeted studies on Neuroendocrine Cancers, including small cell lung cancer and other specialized cancer types. Research focuses on advanced treatment options for patients with limited therapeutic alternatives.

  • Small Cell Lung Cancer
  • Neuroendocrine Carcinoma
  • Advanced Cancer Therapies

Trials evaluate new therapeutic approaches for patients who have progressed after standard treatments.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.